Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- RaQualia Begins PI Study for 5-HT4 Partial Agonist in UK
June 5, 2012
- Eisai Files for Triple Formulation Packs Including Pariet for H. Pylori Eradication
June 4, 2012
- SymBio to Postpone Filing for Supplemental NDA of Treakisym for Indication of Aggressive NHL
June 4, 2012
- Janssen Research & Development Files NDA for MTPC’s SGLT-2 Canagliflozin in the US
June 4, 2012
- Sawai Ranked Forerunner Among Drug Makers to Sell 3 Major Generics: Pharmacist Survey
June 1, 2012
- Ono Pharmaceutical to Collaborate with UK Company in Research of Drug Targets for Allergic Diseases
June 1, 2012
- Taiho to Initiate Global PIII Trial for Anticancer Agent TAS-102 in June
June 1, 2012
- MicroBiopharm Japan Announces Joint R&D Agreement with Eisai in Search of Compounds Derived from Natural Substances
June 1, 2012
- “Some Aspects Might Have Been Overlooked” in Actavis Adaptation Scenario: ASKA President Yamaguchi
May 31, 2012
- CJ CheilJedang of Korea to hold R&D Forum with 6 Ventures in Japan
May 31, 2012
- Kyowa Kirin Launches Its First Antibody Drug Poteligeo for ATL
May 31, 2012
- Pfizer Launches ALK Inhibitor Xalkori, Administered to 51 Patients Prior to NHI Price Listing
May 30, 2012
- Kyorin Holdings to Boost Manufacturing System with Transfer of MSD Plant
May 30, 2012
- Shionogi Launches Oxycodone Injections in Response to Request for Development
May 30, 2012
- Takeda Launches ARB Azilva; Will Target Patients Inadequately Controlled with Existing Medications
May 30, 2012
- Cardiovascular Agent Market Increases 2.6% to 1.363 Billion Yen in 2011: Fuji-Keizai
May 30, 2012
- Takeda to Acquire Multilab of Brazil to Boost Business Infrastructure through OTC Drugs
May 29, 2012
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…